Biological therapy in elderly patients with acute myeloid leukemia

References

• Sekeres MA, Guyatt G, Abel G, et al. American society of hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020;4:3528–3549.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562–569.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8:e481–e491.
   PubMed Web of Science ®Google Scholar
• Laribi K, Sobh M, Ghez D, et al. Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review. Ann Hematol. 2021;100:1359–1376.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Maiti A, Rausch CR, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020;7:e724–e736.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:216–228. Internet].
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383:617–629.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791–803.
   PubMed Web of Science ®Google Scholar
• Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia. 2005;19:176–182.
   PubMed Web of Science ®Google Scholar
• Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121:4854–4860.
   PubMed Web of Science ®Google Scholar
• Burnett A, Cavenagh J, Russell N, et al. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial. Haematologica. 2016;101:724–731.
   PubMed Web of Science ®Google Scholar
• Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379:1508–1516.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012;30:3924–3931.
   PubMed Web of Science ®Google Scholar
• Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15:986–996.
   PubMed Web of Science ®Google Scholar
• Balaian L, Ball ED, Balaian L, et al. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk. Leukemia. 2006;20:2093–2101.
   PubMed Web of Science ®Google Scholar
• Vhj VDV, Boeckx N, Jedema I, et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia. 2004;18:983–988.
   PubMed Web of Science ®Google Scholar
• Nand S, Othus M, Godwin JE, et al. A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood. 2013;122:3432–3439.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–3485.
   PubMed Web of Science ®Google Scholar
• Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104:1442–1452.
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Tanaka TN, Balaian L, et al. A phase I/II trial of the combination of azacitidine and gemtuzumab ozogamicin for treatment of relapsed acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2018;18:346–352.e5. Internet
   PubMed Web of Science ®Google Scholar
• Budaeva I, Zaytsev D, Shatilova A, et al. AML-288: the combination of gemtuzumab ozogamicin and azacitidine in the treatment of relapsed and refractory AML. Clin Lymphoma Myeloma Leuk Internet]. 2021;21:S301. [cited 2022 Aug 8]. DOI:10.1016/S2152-2650(21)01716-X.
   Web of Science ®Google Scholar
• Walter RB, Medeiros BC, Gardner KM, et al. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study. Haematologica. 2014;99:54–59.
   PubMed Web of Science ®Google Scholar
• Stein EM, Walter RB, Erba HP, et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 2018;131:387–396.
   PubMed Web of Science ®Google Scholar
• Fathi AT, Erba HP, Lancet JE, et al. A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood. 2018;132:1125–1133.
   PubMed Web of Science ®Google Scholar
• Wang ES, Adés L, Fathi AT, et al. CASCADE: a phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol. 2017;35:TPS7066TPS7066. Internet:TPS7066TPS7066. Internet
   Web of Science ®Google Scholar
• Abedin S, Guru Murthy GS, Runaas L, et al. Lintuzumab Ac-225 in combination with CLAG-M chemotherapy in relapsed/refractory AML: interim results of a phase I study. Blood. 2019;134:2605. Internet
   Web of Science ®Google Scholar
• Garg R, Allen KJH, Dawicki W, et al. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models. Cancer Med. 2021;10:1128–1140.
   PubMed Web of Science ®Google Scholar
• Ong F, Kim K, Konopleva MY. Venetoclax resistance: mechanistic insights and future strategies. Cancer Drug Resist. 2022;5:380–400.
   PubMedGoogle Scholar
• Hegazi MM, Harpel JG, Miao S, et al. Lintuzumab-225Ac in combination with venetoclax in relapsed/refractory AML: early results of a phase I/II study. Blood Internet]. 2020;136:24–25
   PubMedGoogle Scholar
• Perriello VM, Gionfriddo I, Rossi R, et al. CD123 is consistently expressed on NPM1-mutated AML cells. Cancers (Basel). 2021;14:13.
   PubMedGoogle Scholar
• Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777–1784.
   PubMed Web of Science ®Google Scholar
• Muñoz L, Nomdedéu JF, López O, et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica. 2001;86:1261–1269.
   PubMed Web of Science ®Google Scholar
• Brizzi MF, Garbarino G, Rossi PR, et al. Interleukin 3 stimulates proliferation and triggers endothelial-leukocyte adhesion molecule 1 gene activation of human endothelial cells. J Clin Invest. 1993;91:2887–2892.
   PubMed Web of Science ®Google Scholar
• Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124:385–392.
   PubMed Web of Science ®Google Scholar
• Mani R, Goswami S, Gopalakrishnan B, et al. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34 + CD123 + cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors. Haematologica. 2018;103:1288–1297.
   PubMed Web of Science ®Google Scholar
• Frankel A, Liu J-S, Rizzieri D, et al. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma. 2008;49:543–553.
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380:1628–1637.
   PubMed Web of Science ®Google Scholar
• Lane A, Sweet K, Wang E, et al. Results from ongoing phase 2 trial of SL-401 as consolidation therapy in patients with acute myeloid leukemia (AML) in remission with high relapse risk including minimal residual disease (MRD). Blood. 2016;128:215.
   Web of Science ®Google Scholar
• Togami K, Pastika T, Stephansky J, et al. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. J Clin Invest. 2019;129:5005–5019.
   PubMed Web of Science ®Google Scholar
• He SZ, Busfield S, Ritchie DS, et al. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leuk Lymphoma. 2015;56:1406–1415.
   PubMed Web of Science ®Google Scholar
• Kubasch AS, Schulze F, Giagounidis A, et al. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia. 2020;34:1182–1186.
   PubMed Web of Science ®Google Scholar
• Peipert JD, Efficace F, Pierson R, et al. Patient-reported outcomes predict overall survival in older patients with acute myeloid leukemia. J Geriatr Oncol. 2021;13:935–939.
   PubMed Web of Science ®Google Scholar
• Kovtun Y, Jones GE, Adams S, et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv. 2018;2:848–858.
   PubMed Web of Science ®Google Scholar
• Daver NG, Montesinos P, DeAngelo DJ, et al. Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC), in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood. 2019;134:734.
   Web of Science ®Google Scholar
• Daver N, Aribi A, Montesinos P, et al. Safety and efficacy from a phase 1b/2 study of IMGN632 in combination with azacitidine and venetoclax for patients with CD123-positive acute myeloid leukemia. Blood. 2021;138:372.
   Google Scholar
• Daver NG, Wang ES, Sweet KL, et al. A phase Ib/II study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive acute myeloid leukemia. J Clin Oncol. 2020;38:TPS7564TPS7564. Internet:TPS7564TPS7564. Internet
   Web of Science ®Google Scholar
• Guy DG, Uy GL. Bispecific antibodies for the treatment of acute myeloid leukemia. Curr Hematol Malig Rep. 2018;13:417–425. Internet
   PubMed Web of Science ®Google Scholar
• Friedrich M, Henn A, Raum T, et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014;13:1549–1557.
   PubMed Web of Science ®Google Scholar
• Laszlo GS, Gudgeon CJ, Harrington KH, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood. 2014;123:554–561.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Stein AS, Kantarjian HM, et al. A phase 1 first-in-human study of AMG 330, an anti-CD33 bispecific T-cell engager (BiTE®) antibody construct, in relapsed/refractory acute myeloid leukemia (R/R AML). Blood. 2018;132:25. Internet.
   Web of Science ®Google Scholar
• Ravandi F, Walter RB, Subklewe M, et al. Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML). J Clin Oncol. 2020;38:7508. Internet
   Web of Science ®Google Scholar
• Krupka C, Kufer P, Kischel R, et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia. 2016;30:484–491.
   PubMed Web of Science ®Google Scholar
• Subklewe M, Stein A, Walter RB, et al. Preliminary results from a phase 1 first-in-human study of AMG 673, a novel half-life extended (HLE) anti-CD33/CD3 BITE® (Bispecific T-Cell Engager) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Blood. 2019;134:833. Internet
   Web of Science ®Google Scholar
• Westervelt P, Cortes JE, Altman JK, et al. Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2:2) CD33/CD3 T-cell engager, in patients with relapsed/refractory acute myeloid leukemia (AML). Blood. 2019;134:834. Internet
   Web of Science ®Google Scholar
• Mettu NB, Starodub A, Saa P-P, et al. Results of a phase 1 dose-escalation study of AMV564, a novel T-cell engager, alone and in combination with pembrolizumab in patients with relapsed/refractory solid tumors. J Clin Oncol. 2021;39:2555. Internet
   Google Scholar
• Chichili GR, Huang L, Li H, et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med. 2015;7:289ra82.
   PubMed Web of Science ®Google Scholar
• Al-Hussaini M, Rettig MP, Ritchey JK, et al. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. Blood. 2016;127:122–131.
   PubMed Web of Science ®Google Scholar
• Uy GL, Aldoss I, Foster MC, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021;137:751–762.
   PubMed Web of Science ®Google Scholar
• Jacobs K, Viero C, Godwin J, et al. Management of cytokine release syndrome in AML patients treated with flotetuzumab, a CD123 x CD3 bispecific dart® molecule for T-cell redirected therapy. Blood. 2018;132:2738. Internet
   Web of Science ®Google Scholar
• Uy GL, Rettig MP, Vey N, et al. Phase 1 cohort expansion of flotetuzumab, a CD123×CD3 bispecific dart® protein in patients with relapsed/refractory acute myeloid leukemia (AML). Blood Internet]. 2018;132:764
   Web of Science ®Google Scholar
• Rutella S, Church SE, Vadakekolathu J, et al. Adaptive immune gene signatures correlate with response to flotetuzumab, a CD123 × CD3 bispecific dart® molecule, in patients with relapsed/refractory acute myeloid leukemia. Blood. 2018;132:444. Internet
   Web of Science ®Google Scholar
• Vergez F, Green AS, Tamburini J, et al. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a groupe ouest-est des leucemies aigues et maladies du sang (GOELAMS) study. Haematologica. 2011;96:1792–1798.
   PubMed Web of Science ®Google Scholar
• Vadakekolathu J, Lai C, Reeder S, et al. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. Blood Adv. 2020;4:5011–5024.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Bashey A, Stock W, et al. Complete responses in relapsed/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of vibecotamab (XmAb14045), a CD123 x CD3 T cell-engaging bispecific antibody; initial results of a phase 1 study. Blood. 2020;136:4–5. Internet
   PubMed Web of Science ®Google Scholar
• Zhao X, Singh S, Pardoux C, et al. O riginal A rticles Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica. 2010;95:71–78.
   PubMed Web of Science ®Google Scholar
• Van RA, Van DGAMS, Rombouts EJ, et al. The novel AML stem cell – associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110:2659–2666.
   PubMed Web of Science ®Google Scholar
• Morsink LM, Walter RB, Ossenkoppele GJ. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. Blood Rev. 2019;34:26–33.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Cortes J, Huls G, et al. Update from the ongoing phase I multinational study of MCLA-117, a bispecific CLEC12A x CD3 T-cell engager, in patients (pts) with acute myelogenous leukemia (AML). EHA Library. 2020;294456:EP538. [cited 2021 May 6] . Available from: https://library.ehaweb.org/eha/2020/eha25th/294456/john.mascarenhas.update.from.the.ongoing.phase.i.multinational.study.of.html
   Google Scholar
• Vallera DA, Felices M, McElmurry R, et al. IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function. Clin Cancer Res an off J Am Assoc Cancer Res. 2016;22:3440–3450.
   PubMed Web of Science ®Google Scholar
• Warlick ED, Weisdorf DJ, Vallera DA, et al. GTB-3550 TriKETM for the treatment of high-risk myelodysplastic syndromes (MDS) and refractory/relapsed acute myeloid leukemia (AML) safely drives natural killer (NK) cell proliferation at initial dose cohorts. Blood Internet]. 2020;136:7–8
   Google Scholar
• US A, Pmm VH, Schirm D, et al. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. Leukemia. 2021;35:1586–1596.
   PubMed Web of Science ®Google Scholar
• Zhang L, Gajewski TF, Kline J. Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009;114:1545–1552. Internet
   PubMed Web of Science ®Google Scholar
• Williams P, Basu S, Garcia-Manero G, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125:1470–1481.
   PubMed Web of Science ®Google Scholar
• Jiang H, Fu R, Wang H, et al. CD47 is expressed abnormally on hematopoietic cells in myelodysplastic syndrome. Leuk Res Internet]. 2013;37:907–910
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Jamieson CHM, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138:271–285. Internet
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Boss I, Beach CL, et al. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Blood Adv. 2022;6:2219–2229.
   PubMed Web of Science ®Google Scholar
• Saxena K, Herbrich SM, Pemmaraju N, et al. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer. 2021;127:3761–3771.
   PubMed Web of Science ®Google Scholar
• Daver N, Garcia-Manero G, Basu S, et al. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase ii study. Cancer Discov. 2019;9:370–383. Internet
   PubMed Web of Science ®Google Scholar
• Costello C, Liguori R, Savell A, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375(2):143-153.
   Web of Science ®Google Scholar
• Vago L, Perna SK, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361:478–488.
   PubMed Web of Science ®Google Scholar
• Daver NG, Garcia-Manero G, Konopleva MY, et al. Azacitidine (AZA) with nivolumab (Nivo), and AZA with nivo + ipilimumab (Ipi) in relapsed/refractory acute myeloid leukemia: a non-randomized, prospective, phase 2 study. Blood. 2019;134:830. Internet
   Web of Science ®Google Scholar
• Ravandi F, Assi R, Daver N, et al. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019;6:e480–e488. Internet
   PubMed Web of Science ®Google Scholar
• Reville PK, Kantarjian HM, Ravandi F, et al. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J. 2021;11:60. Internet
   PubMed Web of Science ®Google Scholar
• Gojo I, Stuart RK, Webster J, et al. Multi-center phase 2 study of pembroluzimab (pembro) and azacitidine (AZA) in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed (≥65 years) AML patients. Blood. 2019;134:832. Internet
   Web of Science ®Google Scholar
• Goswami M, Gui G, Dillon LW, et al. Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. J Immunother Cancer. 2022;10(1):e003392.
   Web of Science ®Google Scholar
• Zeidner JF, Vincent BG, Ivanova A, et al. Phase II trial of pembrolizumab after high-dose cytarabine in relapsed/refractory acute myeloid leukemia. Blood Cancer Discov. 2021;2:616–629.
   PubMedGoogle Scholar
• NP T, Kumar V, Moore DT, et al. Safety and efficacy of pembrolizumab prior to allogeneic stem cell transplantation for acute myelogenous leukemia. Transplant Cell Ther. Internet]. 2021;27:1021.e1–1021.e5. [cited 2022 May 12]. Available from: https://www.sciencedirect.com/science/article/pii/S2666636721011714
   PubMedGoogle Scholar
• Zeidan AM, Boddu PC, Wood BL, et al. Blast MRD AML-1 trial: blockade of PD-1 added to standard therapy to target measurable residual disease in acute myeloid leukemia (AML) 1- an investigator-initiated, CTEP-sponsored, randomized phase 2 study of the anti-PD-1 antibody pembrolizumab in combi. Blood. 2020;136:15. Internet
   Web of Science ®Google Scholar
• Zeidan AM, Boddu P, Wood BL, et al. Blast MRD AML-2: blockade of PD-1 added to standard therapy to target measurable residual disease (MDR) in acute myeloid leukemia (AML) 2- a randomized phase 2 study of the venetoclax, azacitidine, and pembrolizumab versus venetoclax and azacitidine as fi. Blood. 2020;136:11–12. Internet
   PubMed Web of Science ®Google Scholar
• Jiang Z, Sun H, Yu J, et al. Targeting CD47 for cancer immunotherapy. J Hematol Oncol. 2021;14:180. Internet
   PubMed Web of Science ®Google Scholar
• Sallman DA, Asch AS, Al Malki MM, et al. The first-in-class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in mds and aml patients: ongoing phase 1b results. Blood. 2019;134:569. Internet
   Web of Science ®Google Scholar
• Sallman DA, Al Malki M, Asch AS, et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: phase Ib results. J Clin Oncol. 2020;38:7507. Internet
   Web of Science ®Google Scholar
• Daver NG, Vyas P, Kambhampati S, et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: phase 1b results. J Clin Oncol. 2022;40:7020. Internet
   Web of Science ®Google Scholar
• Chen JY, McKenna KM, Choi TS, et al. RBC-specific CD47 pruning confers protection and underlies the transient anemia in patients treated with anti-CD47 antibody 5F9. Blood. 2018;132:2327. Internet
   Web of Science ®Google Scholar
• Khandelwal S, Van Rooijen N, Saxena RK. Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation. Transfusion Internet]. 2007;47:1725–1732. [cited 2022 July 4]. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1537-2995.2007.01348.x
   PubMed Web of Science ®Google Scholar
• Daver N, Konopleva M, Maiti A, et al. Phase I/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed older/unfit or high-risk acute myeloid leukemia (AML) and relapsed/refractory (R/R) AML. Blood. Internet]. 2021;138:371.
   Web of Science ®Google Scholar
• Daver N, Vyas P, Chao M, et al. A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia. Blood. 2021;138:3426. Internet
   Web of Science ®Google Scholar
• Garcia-Manero G, Erba HP, Sanikommu SR, et al. Evorpacept (ALX148), a CD47-blocking myeloid checkpoint inhibitor, in combination with azacitidine: a phase 1/2 study in patients with myelodysplastic syndrome (ASPEN-02). Blood. 2021;138:2601. Internet
   PubMed Web of Science ®Google Scholar
• Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276:97–111.
   PubMed Web of Science ®Google Scholar
• Gonçalves Silva I, Yasinska IM, Sakhnevych SS, et al. The tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells. eBioMedicine. 2017;22:44–57. Internet
   PubMed Web of Science ®Google Scholar
• Brunner AM, Esteve J, Porkka K, et al. Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (hmas) in patients (pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): final analysis from a phase ib study. Blood. 2021;138:244. Internet
   Web of Science ®Google Scholar
• Zeidan AM, Al-Kali A, Borate U, et al. Sabatolimab (MBG453) combination treatment regimens for patients (Pts) with higher-risk myelodysplastic syndromes (HR-MDS): the MDS studies in the stimulus immuno-myeloid clinical trial program. Blood. 2021;138:4669. Internet
   Web of Science ®Google Scholar
• Zeidan AM, Westermann J, Kovacsovics T, et al. P582: first results of a phase ii study (stimulus-aml1) investigating sabatolimab + azacitidine + venetoclax in patients with newly diagnosed acute myeloid leukemia. HemaSphere. Internet]. 2022;6
   Google Scholar
• Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18:85–100.
   PubMed Web of Science ®Google Scholar
• Purdy AK, Campbell KS. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther. 2009;8:2211–2220.
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–2100.
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007;110:433–440.
   PubMed Web of Science ®Google Scholar
• Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116:2411–2419.
   PubMed Web of Science ®Google Scholar
• Savani BN, Mielke S, Adams S, et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia. 2007;21:2145–2152.
   PubMed Web of Science ®Google Scholar
• Heidenreich S, Kröger N. Reduction of relapse after unrelated donor stem cell transplantation by KIR-based graft selection. Front Immunol. 2017;8:41.
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051–3057.
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:955–959.
   PubMed Web of Science ®Google Scholar
• Curti A, Ruggeri L, D’Addio A, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood. 2011;118:3273–3279.
   PubMed Web of Science ®Google Scholar
• Curti A, Ruggeri L, Parisi S, et al. Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients. Clin Cancer Res. 2016;22:1914–1921.
   PubMed Web of Science ®Google Scholar
• Parisi S, Ruggeri L, Dan E, et al. Long-term outcome after adoptive immunotherapy with natural killer cells: alloreactive NK cell dose still matters. Front Immunol. 2022;12:1–6.
   Web of Science ®Google Scholar
• Bednarski JJ, Zimmerman C, Berrien-Elliott MM, et al. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant. Blood. 2022;139:1670–1683. Internet
   PubMedGoogle Scholar
• Romee R, Rosario M, Berrien-Elliott MM, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8:357ra123.
   PubMed Web of Science ®Google Scholar
• Cooper MA, Elliott JM, Keyel PA, et al. Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A. 2009;106:1915–1919.
   PubMed Web of Science ®Google Scholar
• Seliger B, Koehl U. Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies. Front Immunol. 2022;13:1–13.
   Web of Science ®Google Scholar
• Gurney M, O’Dwyer M, Tzelepi V. Realizing InnatePotential: CAR-NK cell therapies for acute myeloid leukemia. Cancers (Basel). 2021;14:13.
   PubMedGoogle Scholar
• Tang X, Yang L, Li Z, et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018;8:1083–1089.
   PubMed Web of Science ®Google Scholar
• Dong H, Ham JD, Hu G, et al. Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia. Proc Natl Acad Sci U S A. 2022;119:e2122379119.
   PubMedGoogle Scholar
• Albinger N, Pfeifer R, Nitsche M, et al. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia. Blood Cancer J. 2022;12:61.
   PubMed Web of Science ®Google Scholar
• Vishwasrao P, Li G, Boucher JC, et al. Emerging CAR T cell strategies for the treatment of AML. Cancers (Basel). 2022;14:1–26.
   Web of Science ®Google Scholar
• Liu F, Zhang H, Sun L et al. 2020. FIRST-IN-HUMAN CLL1-CD33 COMPOUND CAR (CCAR) T CELL THERAPY IN RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA . (Abstract release date: 05/14/20) EHA Library. 294969; S149
   Google Scholar
• Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020;111:312–322 doi:10.1111/cas.14274. :
   PubMed Web of Science ®Google Scholar
• Borthakur G, Kantarjian H, Ravandi F, et al. O riginal A rticles Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 2011;96:62–68.
   PubMed Web of Science ®Google Scholar
• Fischer T, Stone RM, Deangelo DJ, et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:4339–4345.
   PubMed Web of Science ®Google Scholar
• Tomlinson BK, Gallogly MM, Kane DM, et al. A phase ii study of midostaurin and 5-azacitidine for untreated elderly and unfit patients with FLT3 wild-type acute myelogenous leukemia. Clin Lymphoma Myeloma Leuk. 2020;20:226–233.e1. Internet
   PubMed Web of Science ®Google Scholar
• Strati P, Kantarjian H, Ravandi F, et al. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. [Internet]. 2015;90:276–281. [cited 2021 Jul 04]. Available from:https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.23924
   PubMed Web of Science ®Google Scholar
• Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381:1728–1740.
   PubMed Web of Science ®Google Scholar
• Perl AE, Larson RA, Podoltsev NA, et al. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022;139:3366–3375.
   PubMed Web of Science ®Google Scholar
• Daver N, Altman JK, Maly J, et al. Efficacy and safety of venetoclax in combination with gilteritinib for relapsed/refractory FLT3-mutated acute myeloid leukemia in the expansion cohort of a phase 1b study. Blood. 2020;136:20–22.
   Google Scholar
• Wang ES, Montesinos P, Minden MD, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed flt3mut+ aml ineligible for intensive chemotherapy. Blood. 2022;140(17):1845-1857.
   Google Scholar
• Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20:984–997.
   PubMed Web of Science ®Google Scholar
• Swaminathan M, Kantarjian HM, Levis M, et al. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021;106:2121–2130.
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Kantarjian HM, Muftuoglu M, et al. Quizartinib with decitabine ± venetoclax is highly active in patients (Pts) with FLT3 -ITD mutated (mut) acute myeloid leukemia (AML): clinical report and signaling cytof profiling from a phase IB/II trial. Blood. 2020;136:19–20. Internet
   Web of Science ®Google Scholar
• Erba H, Montesinos P, Vrhovac R, et al. AML-029 quizartinib prolonged overall survival (OS) vs placebo plus intensive induction and consolidation therapy followed by single-agent continuation in patients aged 18-75 years with newly diagnosed FLT3–internal tandem duplication positive (flt3-ITD+) acute myeloid leukemia (AML). Clin Lymphoma Myeloma Leuk. 2022;22:S208–S209.
   Google Scholar
• Wang ES, Goldberg AD, Walter RB, et al. Long-term results of a phase 2 trial of crenolanib combined with 7+3 chemotherapy in adults with newly diagnosed FLT3 mutant AML. J Clin Oncol [Internet]. 2022;40:7007
   Web of Science ®Google Scholar
• Wang ES, Griffiths EA, Walter RB, et al. Tolerability and efficacy of crenolanib and cytarabine/anthracycline chemotherapy in older patients (Aged 61 to 75) with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). Blood. 2019;134:3829. Internet
   Web of Science ®Google Scholar
• Maiti A, DiNardo CD, Daver NG, et al. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021;112(11):1–6.
   Google Scholar
• Short NJ, DiNardo CD, Daver N, et al. A triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia: results from a phase I/II study. Blood. 2021;138:696. Internet
   Google Scholar
• Medeiros BC, Fathi AT, DiNardo CD, et al. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017;31:272–281.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Schuh AC, Stein EM, et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021;22:1597–1608. Internet
   PubMed Web of Science ®Google Scholar
• Chan SM, Cameron C, Cathelin S, et al. Enasidenib in combination with venetoclax in IDH2-mutated myeloid malignancies: preliminary results of the phase Ib/II enaven-AML trial. Blood. 2021;138:1263. Internet
   Web of Science ®Google Scholar
• Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386:1519–1531. Internet
   PubMed Web of Science ®Google Scholar
• Lachowiez CA, Garcia JS, Borthakur G, et al. A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated hematologic malignancies. J Clin Oncol. 2022;40:7018. Internet
   Web of Science ®Google Scholar
• Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33:379–389.
   PubMed Web of Science ®Google Scholar
• Konopleva MY, Röllig C, Cavenagh J, et al. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial. Blood Adv. 2022;6:4147–4156.
   PubMed Web of Science ®Google Scholar
• Yokoyama A, Somervaille TCP, Smith KS, et al. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell. 2005;123:207–218.
   PubMed Web of Science ®Google Scholar
• Xirodimas DP, Saville MK, Bourdon J-C, et al. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell. 2004;118:83–97.
   PubMed Web of Science ®Google Scholar
• McKeown MR, Corces MR, Eaton ML, et al. Superenhancer analysis defines novel epigenomic subtypes of non-APL AML, including an RARα dependency targetable by SY-1425, a potent and selective RARα agonist. Cancer Discov. 2017;7:1136–1153.
   PubMed Web of Science ®Google Scholar
• Short NJ, Montalban-Bravo G, Alvarado Y, et al. Azacitidine, venetoclax and pevonedistat as frontline therapy for patients with secondary acute myeloid leukemia who are unfit for intensive chemotherapy: results from a phase I/II study. Blood. 2021;138:2349.
   Google Scholar
• Sallman DA, DeZern AE, Garcia-Manero G, et al. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39:1584–1594.
   PubMed Web of Science ®Google Scholar
• Sallman DA, Komrokji RS, DeZern AE, et al. Long term follow-up and combined phase 2 results of eprenetapopt (APR-246) and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML). Blood. 2021;138:246. Internet
   PubMed Web of Science ®Google Scholar
• Maiti A, Daver NG. Eprenetapopt in the post-transplant setting: mechanisms and future directions. J Clin Oncol. 2022;40(34):3994-3997.
   Web of Science ®Google Scholar
• Thorsteinsdottir U, Kroon E, Jerome L, et al. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol. 2001;21:224–234.
   PubMed Web of Science ®Google Scholar
• Alcalay M, Tiacci E, Bergomas R, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood. 2005;106:899–902.
   PubMed Web of Science ®Google Scholar
• Li BE, Gan T, Meyerson M, et al. Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells. Blood. 2013;122:2039–2046.
   PubMed Web of Science ®Google Scholar
• Erba HP, Fathi AT, Issa GC, et al. Update on a phase 1/2 first-in-human study of the menin-KMT2A (MLL) inhibitor ziftomenib (KO-539) in patients with relapsed or refractory acute myeloid leukemia. Blood. 2022;140:153–156. Internet
   Google Scholar
• Issa GC, Aldoss I, DiPersio JF, et al. The menin inhibitor SNDX-5613 (revumenib) leads to durable responses in patients (Pts) with KMT2A-rearranged or NPM1 mutant AML: updated results of a phase (Ph) 1 study. Blood. 2022;140:150–152. Internet
   Google Scholar
• Issa GC, Ravandi F, DiNardo CD, et al. Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021;35:2482–2495. Internet
   PubMed Web of Science ®Google Scholar
• de Botton S, Cluzeau T, Vigil CE, et al. Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML. Blood Adv. 2022
   PubMedGoogle Scholar
• Willekens C, Chraibi S, Decroocq J, et al. Reduced venetoclax exposition to seven days of azacitidine is efficient in treatment-naïve patients with acute myeloid leukemia. Blood. 2022;140:537–538. Internet
   Google Scholar
• Pratz KW, Chai X, Xie J, et al. Cost-effectiveness analysis of venetoclax in combination with azacitidine versus azacitidine monotherapy in patients with acute myeloid leukemia who are ineligible for intensive chemotherapy: from a us third party payer perspective. Pharmacoeconomics. 2022;40:777–790.
   PubMed Web of Science ®Google Scholar
• Imataki O, Ishida T, Kida J-I, et al. Cost-effectiveness analysis of transplantation-ineligible elderly patients with acute leukemia harboring a molecular target: ph-positive acute leukemia and FLT3-mutated acute myeloid leukemia. J Clin Med Res. 2022;14:432–435.
   PubMedGoogle Scholar